Eisai Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Haruo Naito
- Full Time Employees
- 10,543
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 4-6-10, Koishikawa Tokyo TY Japan 112-8088
- IPO Date
- Apr 7, 2011
- Website
- eisai.com
- Similar Companies
- Business
- Eisai Co., Ltd. develops, manufactures and markets pharmaceutical products with a focus on neurology and oncology; its core offerings include LEQEMBI (lecanemab) for early Alzheimer's disease approved in 48 countries including Japan, the US, EU, China and South Korea; LENVIMA (lenvatinib) for thyroid, hepatocellular, renal cell and endometrial cancers approved in over 80 countries; Dayvigo (lemborexant) for insomnia approved in over 25 countries; Fycompa (perampanel) for partial-onset and primary generalized tonic-clonic seizures approved in over 75 countries; and other key products such as Aricept (donepezil) for Alzheimer's dementia, Halaven (eribulin) for metastatic breast cancer, Zonegran (zonisamide) for seizures, Aciphex/Pariet (rabeprazole) for gastroesophageal reflux, Aloxi (palonosetron) for chemotherapy-induced nausea, and consumer healthcare items including over-the-counter drugs, diagnostics and chemicals. Eisai operates through segments encompassing prescription pharmaceuticals, generics, consumer health care and other businesses; it serves patients, healthcare providers and daily living domains globally with manufacturing sites in Japan, the US, China, Indonesia, Taiwan, India and the UK, and marketing in Asia-Pacific, Americas, EMEA, China and Latin America regions. Founded in 1941 and headquartered in Tokyo, Japan, the company maintains research hubs in Japan, the US and UK, employs around 10,000 people with 1,500 in R&D, and trades under ticker ESALF. Recent developments include the March 2025 tender offer to acquire EcoNaviSta Inc. for synergies in dementia platform solutions via elderly monitoring SaaS; a strategic research collaboration with SEED Therapeutics in 2024 on neurodegeneration and cancer backed by up to $1.5 billion in milestones and Series A-3 financing led by Eisai; divestiture of European and UK rights to Targretin in January 2025; major expansion of Canadian operations in Mississauga growing headcount by 246% since 2020; regulatory advancements for LEQEMBI subcutaneous formulation with US FDA Fast Track for initiation-to-maintenance treatment and Japan approval application; and ongoing investments such as up to $15 million in C2N Diagnostics.
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
BioArctic Interim Report for the period January - March 2026
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
BioArctic Interim Report for the period October - December 2025
Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Eisai Co., Ltd. (ESAIY) Q2 2026 Earnings Call Transcript
Merck, Eisai discontinue late-stage study for liver cancer therapy